Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics

20th July 2018 (Last Updated August 12th, 2019 10:38)

Pliant Therapeutics has raised $62m through a series B financing round from Cowen Healthcare Investments.

Pliant Therapeutics has raised $62m through a series B financing round from Cowen Healthcare Investments.

The funding round also included participation from new investors and undisclosed institutional investors.

The company plans to use the funds raised towards the initiation of clinical trials in idiopathic pulmonary fibrosis (IPF) and to advance therapies for fibrotic diseases.

Based in the US, Pliant Therapeutics is a biotechnology company engaged in the development of therapeutics for fibrotic diseases.

MolMed has signed an agreement with GlaxoSmithKline (GSK) to manufacture lentiviral vectors meant for clinical application in GSK’s oncology programme.

Based in Italy, MolMed is a biotechnology company engaged in the development of cell and gene therapies for cancer and other rare diseases, while GSK is a UK-based pharmaceutical company.

Modus Therapeutics has raised Skr140m ($15.8m) in a financing round from Swedish venture capital firm HealthCap.

The funds are intended to be used towards clinical trials of the company’s drug sevuparin, which is indicated for the treatment of sickle cell disease.

Modus Therapeutics is a Swedish drug development company engaged in the development of pharmaceutical therapies.

Urovant Sciences has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $150m through an initial public offering of shares of its common stock.

The underwriters will receive a 30-day option to buy additional shares of the company’s common stock.

The company plans to use the funds towards clinical development, working capital, and general corporate purposes.

J.P. Morgan Securities, Jefferies and Cowen and Company were appointed as underwriters to the company for the offering.

Based in the UK, Urovant is a biopharmaceutical company engaged in the development of innovative therapies for urologic diseases.

"Modus Therapeutics has raised Skr140m ($15.8m) in a financing round from Swedish venture capital firm HealthCap."

Liquidia Technologies has raised $62.73m through a public offering of 5.2 million shares of its common stock priced at $12 a share.

The underwriters will receive a 30-day option to buy additional shares of the company’s common stock.

The company plans to use the funds towards clinical development, working capital, and other general corporate purposes.

DLA Piper (US) has been appointed as the legal adviser to the company for the offering.

Based in the US, Liquidia Technologies is a clinical biopharmaceutical company engaged in the discovery and development of human therapies.

Compass Therapeutics has raised $49m to complete its planned total $132m series A financing from OrbiMed Advisors and F-Prime Capital.

Investors Cowen Healthcare Investments, Biomatics Capital, Ulysses Holdings, Alexandria Venture Investments and Biomed Realty Ventures also participated in the funding round.

Compass Therapeutics is a biotechnology company engaged in the discovery and development of therapeutic antibodies for cancer treatment.

The transaction enables Compass Therapeutics to expand its antibody-based therapeutics and for the advancement of its immuno-oncology drug candidate, CTX-471.

All companies involved in the transaction are based in the US.

Eurobio Scientific (formerly Diaxonhit) has completed the acquisition of Dendritics SAS for an undisclosed cash consideration.

Based in France, Eurobio is a biotechnology company focused on the development of in-vitro diagnostics, while Dendritics, also based in France, is a developer of monoclonal antibodies.

The transaction enables the acquirer company to strengthen its business in the life sciences industry.

Biodesix has completed the acquisition of Integrated Diagnostics (Indi) for an undisclosed sum.

The acquisition will add Indi’s oncology product XL2 test, which is used to improve the diagnosis of lung cancer, to Biodesix’s product portfolio.

Based in the US, Biodesix is a molecular diagnostics company that develops clinical decision-making products, while Integrated Diagnostics, also based in the US, is a developer of blood-based molecular diagnostics.

The transaction enables the acquirer company to expand its lung disease product pipeline.